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Resumo:	  The	  excision	   repair	   cross-­‐complementation	  1	   (ERCC1)	  enzyme	  plays	  an	  essential	   role	   in	   the	  
nucleotide	  excision	  repair	  pathway	  and	  is	  associated	  with	  resistance	  to	  platinum-­‐based	  chemotherapy	  in	  
different	  types	  of	  cancer.	  The	  aim	  of	  the	  present	  study	  was	  to	  evaluate	  the	  clinicopathologic	  significance	  
of	  ERCC1	  expression	  in	  breast	  cancer	  patients.	  We	  used	  immunohistochemical	  analysis	  to	  assess	  ERCC1	  
expression	  in	  a	  tissue	  microarray	  from	  135	  breast	  carcinomas.	  This	  was	  correlated	  with	  clinicopathologic	  
factors	   and	   outcome	   data.	   The	   clinicopathologic	   features	   and	   immunohistochemical	   markers	   of	   the	  
tumors	  were	  compared	  using	  the	  chi-­‐square	  and	  the	  Fisher's	  exact	  test.	  The	  Kaplan-­‐Meier	  method	  was	  
used	  to	  analyze	  overall	  and	  disease-­‐free	  survival.	  ERCC1	  expression	  analysis	  was	  available	  for	  109	  cases.	  
In	  this	  group,	  58	  (53.2%)	  were	  positive	  for	  ERCC1.	  ERCC1-­‐positive	  expression	  was	  correlated	  with	  smaller	  
tumor	  size	  (P	  =	  0.007)	  and	  with	  positivity	  for	  ER	  (estrogen	  receptor)	  (P	  =	  0.040),	  but	  no	  correlation	  was	  
found	  with	  other	  clinicopathological	   features	  or	  biomarkers	   studied.	  ERCC1	  did	  not	  correlate	  with	   the	  
overall	   and	   disease-­‐free	   survival	   rates.	   Although	   not	   statistically	   significant,	   the	   majority	   (72.7%)	   of	  
special	   histological	   types	   of	   invasive	   breast	   carcinomas	  was	   positive	   for	   ERCC1	   compared	   to	   invasive	  
ductal	   carcinomas,	  which	  were	   ERCC1-­‐positive	   in	   51.1%	   of	   the	   cases.	   Similarly,	   triple	   negative	   breast	  
cancers	   (TNBC)	  were	  more	   frequently	  negative	   for	   ERCC1	   (61.5%	  of	   the	   cases)	   compared	   to	   the	  non-­‐
TNBC	  (41.5%).	  In	  conclusion,	  ERCC1	  expression	  correlated	  significantly	  with	  favorable	  prognostic	  factors,	  
such	  as	  smaller	  tumor	  size	  and	  ER-­‐positivity,	  suggesting	  a	  possible	  role	  for	  ERCC1	  as	  a	  predictive	  and/or	  
prognostic	  marker	  in	  breast	  cancer.	  
Palavras-­‐chave:	   excision	   repair	   cross-­‐complementation	   1,	   breast	   cancer,	   breast	   cancer	   molecular	  
subtypes,	  immunohistochemistry.	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Resumo:	  A	  enzima	  “excision	  repair	  cross-­‐complementation	  1”	  (ERCC1)	  desempenha	  um	  papel	  essencial	  
na	  via	  de	  reparação	  do	  DNA	  por	  excisão	  de	  nucleotídeos	  e	  está	  associada	  a	  resistência	  à	  quimioterapia	  
com	  compostos	  derivados	  da	  platina	  em	  diferentes	  tipos	  de	  cancro.	  O	  presente	  estudo	  pretendia	  avaliar	  
o	  significado	  clinicopatológico	  da	  expressão	  de	  ERCC1	  em	  doentes	  com	  cancro	  da	  mama.	  Foi	  utilizada	  
análise	   imunohistoquímica	   para	   avaliar	   a	   expressão	   de	   ERCC1	   num	   “tissue	   microarray”	   de	   135	  
carcinomas	   da	   mama.	   Estes	   dados	   foram	   correlacionados	   com	   fatores	   clinicopatológicos	   e	   com	   o	  
prognóstico	  dos	  doentes.	  As	  características	  clinicopatológicas	  e	  os	  marcadores	  imunohistoquímicos	  dos	  
tumores	   foram	   comparados	   com	   o	   teste	   do	   qui-­‐quadrado	   e	   o	   teste	   exato	   de	   Fisher.	   O	   método	   de	  
Kaplan-­‐Meier	   foi	   utilizado	   para	   avaliar	   a	   sobrevida	   global	   e	   a	   sobrevida	   livre	   de	   doença.	   A	   análise	   da	  
expressão	   de	   ERCC1	   estava	   disponível	   para	   109	   casos.	   Neste	   grupo,	   58	   (53.2%)	   foram	   positivos	   para	  
ERCC1.	  A	  expressão	  positiva	  de	  ERCC1	  foi	  correlacionada	  com	  tumores	  com	  dimensões	  inferiores	  a	  2.0	  
cm	   (P	   =	   0.007)	   e	   com	  positividade	  para	   os	   recetores	   de	   estrogénios	   (RE)	   (P	   =	   0.040),	  mas	   não	  houve	  
correlação	  com	  as	  restantes	  características	  clinicopatológicas	  ou	  biomarcadores	  estudados.	  A	  expressão	  
de	  ERCC1	  não	  teve	  correlação	  com	  as	  taxas	  de	  sobrevida	  global	  e	   livre	  de	  doença	  aos	  5	  anos.	  Embora	  
não	   sendo	   estatisticamente	   significativo,	   a	   maioria	   (72.7%)	   dos	   tipos	   histológicos	   especiais	   de	  
carcinomas	   da	   mama	   foi	   positiva	   para	   ERCC1	   quando	   comparada	   com	   carcinomas	   ductais,	   os	   quais	  
foram	  positivos	  para	  ERCC1	  em	  51.1%	  dos	  casos.	  Da	  mesma	  forma,	  os	  cancros	  da	  mama	  triplo-­‐negativos	  
foram	  mais	   frequentemente	   negativos	   para	   ERCC1	   (61.5%	   dos	   casos)	   comparados	   com	  os	   não-­‐triplo-­‐
negativos	   (41.5%).	   Em	   conclusão,	   a	   expressão	   de	   ERCC1	   correlacionou-­‐se	   de	   forma	   significativa	   com	  
fatores	  de	  prognóstico	  favoráveis,	  tais	  como	  tumores	  de	  pequenas	  dimensões	  	  e	  com	  positividade	  para	  
os	   RE,	   sugerindo,	   assim,	   um	   possível	   papel	   da	   enzima	   ERCC1	   como	   marcador	   preditivo	   e/ou	   de	  
prognóstico	  no	  cancro	  da	  mama.	  
Palavras-­‐chave:	  excision	   repair	   cross-­‐complementation	  1,	   cancro	  da	  mama,	   subtipos	  moleculares	  de	  
cancro	  da	  mama,	  imunohistoquímica	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 2 
Abstract 
 
The excision repair cross-complementation 1 (ERCC1) enzyme plays an 
essential role in the nucleotide excision repair pathway and is associated with 
resistance to platinum-based chemotherapy in different types of cancer. The 
aim of the present study was to evaluate the clinicopathologic significance of 
ERCC1 expression in breast cancer patients. We used immunohistochemical 
analysis to assess ERCC1 expression in a tissue microarray from 135 breast 
carcinomas. This was correlated with clinicopathologic factors and outcome 
data. The clinicopathologic features and immunohistochemical markers of 
the tumors were compared using the chi-square and the Fisher's exact test. 
The Kaplan-Meier method was used to analyze overall and disease-free 
survival. ERCC1 expression analysis was available for 109 cases. In this 
group, 58 (53.2%) were positive for ERCC1. ERCC1-positive expression was 
correlated with smaller tumor size (P = 0.007) and with positivity for ER 
(estrogen receptor) (P = 0.040), but no correlation was found with other 
clinicopathological features or biomarkers studied. ERCC1 did not correlate 
with the overall and disease-free survival rates. Although not statistically 
significant, the majority (72.7%) of special histological types of invasive 
breast carcinomas was positive for ERCC1 compared to invasive ductal 
carcinomas, which were ERCC1-positive in 51.1% of the cases. Similarly, 
triple negative breast cancers (TNBC) were more frequently negative for 
ERCC1 (61.5% of the cases) compared to the non-TNBC (41.5%). In 
conclusion, ERCC1 expression correlated significantly with favorable 
prognostic factors, such as smaller tumor size and ER-positivity, suggesting a 
possible role for ERCC1 as a predictive and/or prognostic marker in breast 
cancer. 
 
Keywords excision repair cross-complementation 1, breast cancer, breast 
cancer molecular subtypes, immunohistochemistry 
  
 3 
Introduction 
 
Breast cancer is a heterogeneous disease with various histological 
types of tumors and different clinical behavior. The molecular classification 
of breast cancer differentiates, at least, three subgroups of tumors: the 
luminal subtype with cells expressing estrogen receptors (ER) and ER-related 
genes; the human epidermal growth factor receptor 2 (HER2)-overexpressing 
subtype; and the basal-like subtype associated with the expression of basal 
cell markers [1-3]. For the clinical management of breast cancer, a useful 
manner of defining the molecular subtypes is the classification of tumors 
using immunohistochemistry or in situ hybridization techniques. 
Immunohistochemical expression of ER and/or progesterone receptors (PR) 
characterizes luminal tumors, and HER2-overexpressing subtype is defined 
by overexpression and/or amplification of HER2. Breast tumors that do not 
express hormone receptors (ER, PR) nor HER2 overexpression and/or 
amplification are classified as triple negative breast cancers (TNBC) [4]. The 
vast majority of TNBC are of basal-like phenotype, but this group of cancers 
also encompasses tumors without the expression of basal markers, including 
the molecular apocrine and claudin-low tumors [5]. 
Well-established targeted therapies are available for breast cancers 
positive for hormone receptors or with a HER2-positive status. Endocrine 
therapy with tamoxifen, an ER modulator, or with aromatase inhibitors is 
advocated for breast cancers that express ER, and anti-HER2 therapy using 
trastuzumab, a monoclonal antibody against HER2, or lapatinip, an inhibitor 
of the tyrosine kinase activity of HER2, for those tumors with overexpression 
and/or amplification of HER2 [6]. In contrast, targeted therapies for TNBC 
are not completely validated and the main treatment for this group of tumors 
is the use of chemotherapy, including platinum salts, isolated or in 
combination with other chemotherapy agents [7, 8]. 
Platinum-based chemotherapy is used in a variety of malignant 
diseases, including tumors from ovary, testes, lung, cervix, colon, and 
bladder. Currently, there are three platinum compounds more commonly 
used, namely cisplatin, carboplatin, and oxaliplatin. Platinum-based drugs 
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provoke the formation of platinum-DNA adducts leading to changes in the 
helical structure of the DNA molecule [9, 10]. The distortion of the DNA 
molecule results in the inhibition of transcription and replication, leading to 
cell death. DNA adducts are recognized and repaired by the nucleotide 
excision repair (NER) pathway, including those caused by platinum 
compounds [9-11]. The excision repair cross-complementation group 1 
(ERCC1) is a nuclease that plays an essential role in the NER pathway: 
ERCC1 forms a heterodimer with xeroderma pigmentosum complementation 
group F (XPF) protein, and the complex ERCC1-XPF executes the excision 
of the damaged DNA [9-12]. Therefore, the integrity of the NER pathway is 
an important predictor of platinum-based chemotherapy resistance [9, 12]. 
Low levels of ERCC1 are correlated with in vitro sensitivity to 
cisplatin in malignant cell lines from cervical cancer [13], testicular cancer 
[14], and malignant effusions collected from patients with gastric, 
gynecological and non-small cell lung cancer (NSCLC) [15]. Retrospective 
clinical studies have shown an association between high levels of ERCC1 
mRNA or protein expression and resistance to platinum-based chemotherapy 
in different types of advanced cancer, including gastric [16] and colorectal 
cancer [17, 18], NSCLC [19, 20], urinary tract cancer [21, 22], and head and 
neck squamous cell carcinoma [23]. 
There are few studies regarding the expression of ERCC1 in breast 
cancer. Some studies showed that the expression of ERCC1 is particularly 
lower in TNBC [24, 25]. On the other hand, increased expression of ERCC1 
has been positively correlated with features related to a better prognosis in 
breast cancer such as patient age > 50 years old, lower T stage, nodal 
negativity, and ER positivity [26]. There are also few studies regarding 
patients with breast cancer that were treated with platinum-based regimens. 
Shao et al. (2010) [27] observed an association between higher ERCC1 
expression and shorter progression-free survival in patients treated with 
paclitaxel plus cisplatin. Another study showed that ERCC1 negative breast 
tumors were associated with a higher pathological complete remission rate in 
patients treated with paclitaxel plus carboplatin in neoadjuvant chemotherapy 
[28]. 
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The aim of this study was to analyze the association between 
clinicopathologic features and the immunohistochemical expression of 
ERCC1 in a series of patients with breast cancer. We also analyzed the 
prognostic significance of ERCC1 in this group of patients. 
 
Materials and Methods 
 
Patients’ characteristics 
All 135 enrolled patients were cases of primary operable invasive 
breast cancer. Patients’ clinical history data was acquired from the files of the 
Department of Pathology, Hospital do Divino Espírito Santo, Azores, 
Portugal. The patients’ age ranged from 24 to 60 years. The histological 
diagnosis of the formalin-fixed paraffin-embedded sections was confirmed by 
three pathologists as follows: 117 invasive ductal carcinomas (86.7%), 4 
invasive lobular carcinomas (3.0%), 1 invasive mixed  (mucinous and ductal) 
breast carcinoma  (0.7%) and 13 invasive breast carcinomas of special 
histological types (9.6%). The latter group included 4 invasive mucinous 
carcinomas (3.0%), 4 invasive cribriform carcinomas (3.0%), 2 invasive 
papillary carcinomas (1.5%), 1 invasive tubular carcinoma (0.7%), 1 invasive 
medullary carcinoma (0.7%), and 1 micropapillary carcinoma (0.7%). 
Multiple clinicopathologic and molecular characteristics were 
obtained, including age, tumor size, histological type, histological grade, 
lymph node status, TNM stage, the Nottingham Prognostic Index (NPI), 
tumor molecular subtype (as defined by the immunohistochemical expression 
of ER, PR, and HER2), and the immunohistochemical expression of Ki-67 
index, epidermal growth factor receptor (EGFR), cytokeratin 5 (CK5), P-
cadherin, and vimentin (Table 1). 
Follow-up ranged from a minimum of 5 months to a maximum of 
117 months (median 77.5 months). Disease-free survival (DFS) time was 
calculated as the duration from the date of surgery to the date of documented 
disease progression (breast-cancer-derived relapse/metastasis) or the date of 
the last follow-up. Overall survival (OS) time was calculated as the duration 
from the date of diagnosis to the date of death or last contact. 
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This study was conducted according to the Portuguese regulative 
law for the usage of biological specimens from tumor banks. In consequence, 
the samples can exclusively be used for research purposes in the context of 
retrospective studies. 
 
Tissue microarray 
A tissue microarray composed of duplicate cores of representative 
areas of the tumors (2 mm in diameter) deposited in a paraffin block was 
developed in accordance with previous work (tissue microarray builder 
ab1802; Abcam, Cambridge, UK) [29, 30]. Normal breast tissue cores were 
used as controls and included in the paraffin block. 
 
Immunohistochemical study 
Immunohistochemistry (IHC) was performed on 3-µm-thick tissue 
sections prepared from formalin-fixed, paraffin-embedded tissue from the 
constructed tissue microarray block. Immunohistochemistry for ER, PR, 
HER2, EGFR, CK5, P-cadherin, vimentin, and Ki-67 was conducted in 
accordance to the techniques, antibodies specifications and assay conditions 
as previously published [30, 31]. 
The expression of ERCC1 was evaluated using a mouse monoclonal 
antibody (clone 8F1, Neomarkers, Fremont, California, USA). Sections were 
deparaffinized with xylene and rehydrated in a series of decreasing 
concentration of ethanol solutions. For epitope retrieval, sections were 
exposed to EDTA buffer (pH 9.0) and heated for 30 minutes in a 98º water 
bath. A 3% hydrogen peroxidase solution was then used to block endogenous 
peroxidase.  Slides were then incubated with the monoclonal antibody at a 
1:100 dilution and were labeled with the Envision Detection System from 
DAKO. DAB plus (3,3’-diaminobenzidine tetrahydrochloride, DAKO 
Glostrup, Denmark) was then applied as chromogenic substrate and 
hematoxylin/ammoniacal water as counterstaining. Sections from normal 
human tonsil tissue were used as an external positive control. For the 
negative control, the primary antibody was replaced with PBS/nonimmune 
mouse serum. 
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A pathologist (RG), who was blinded to the patients’ outcomes, 
assessed the semi-quantitative expression of ERCC1. The scoring system 
used was previously described by Al Haddad et al. (1999) [32] as H score. 
Nuclear staining intensity of ERCC1 protein was graded on a scale from 0 to 
3, with a larger number indicating a higher intensity. The extension of 
staining was categorized as: 0 = no tumor nuclei expression; 0.1 = 1 to 9% of 
positive tumor nuclei; 0.5 = 10 to 49% of positive tumor nuclei; and 1.0 = 
50% or more positive tumor nuclei. The extension score was multiplied by 
the staining intensity of nuclei to obtain a final semi-quantitative H score. 
The cut-off established for separating ERCC1-positive tumors from ERCC1-
negative tumors was the median value of all the H scores. Cores with more 
than 50% of tissue loss or lack of tumor cells were considered not 
interpretable. 
 
Statistical analysis 
Descriptive statistics comparing ERCC1 expression with the 
clinicopathologic characteristics were analyzed by the chi-square test or, 
when necessary, by Fisher's exact test. Survival curves were calculated by the 
Kaplan-Meier method and the differences were assessed by the log-rank test. 
60 months was the maximum cut-off value considered, as it is the expected 
clinical time for breast cancer recurrence. A computer program package 
StataTM (Version 9.2, StataCorp, College Station, TX, USA) was used for all 
statistical testing and management of the database, and a significant level of 
5% was considered statistically significant. 
 
Results 
 
From the total of 135 cases enrolled for this study, ERCC1 
immunohistochemistry analysis was available for 109 cases. ERCC1 
expression was localized to the nucleus of neoplastic cells (Figure 1). The 
median value of H scores was 0.2. Tumors with an H score ≥ 0.2 (i.e., tumors 
with 10% or more positive nuclei for ERCC1 with an immunostaining 
intensity score of 1, and/or tumors with 1% or more positive nuclei for 
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ERCC1 with an immunostaining intensity score of at least 2) were considered 
ERCC1-positive. Of the 109 cases, 58 (53.2%) were positive for ERCC1. 
The expression levels of ERCC1 were compared to 
clinicopathologic features. A significant association was found between 
ERCC1 expression and tumor size smaller than 2.0 cm (P = 0.007). The 
expression of ERCC1 was not significantly related to age (P = 0.154), tumor 
histological grade (P = 0.400), lymph node status (P = 0.565), TNM stage (P 
= 0.290) and NPI (P = 0.508). Although there was no statistical correlation 
between tumor histological type and ERCC1 expression (P = 0.360), 8 of 11 
(72.7%) cases of special types of invasive breast carcinoma were positive for 
ERCC1 compared to 48 of 94 (51.1%) cases of invasive ductal carcinoma 
(Table 2). 
Hormone receptors (ER, PR), HER2, EGFR, CK5, P-cadherin and 
vimentin status were analyzed. ERCC1 expression was significantly 
associated with ER positivity (P = 0.040) but not with the remainder 
biomarkers (Table 3). There was no correlation between the expression of 
ERCC1 and the molecular subtype of breast cancer (P = 0.226). 
Nevertheless, 16 of 26 (61.5%) cases of TNBC were ERCC1 negative, while 
in the non-TNBC group, 34 of 82 (41.5%) cases were negative for ERCC1, 
including 31 and 3 cases of luminal and HER2-overexpressing subtypes, 
respectively (Table 3). 
The five-year OS rate for all patients enrolled in this study was 
69.7% (76 of 109 patients were alive at the end point of the study). There was 
no statistical correlation between ERCC1 expression and OS: the five-year 
OS rates were 67.2% (39 of 58 patients were alive) for patients with ERCC1-
positive tumors and 72.5% for patients with ERCC1-negative tumors (37 of 
51 patients were alive) (P = 0.458). DFS data was available for 84 patients 
and the five-year DFS rate was 81.0% (68 of 84 patients presented no 
progression of their disease at the last follow-up).  There was no statistical 
correlation between ERCC1 expression and DFS: the five-year DFS rates at 
the last follow-up were 75.0% (27 of 36 patients without progression of their 
disease) for patients with ERCC1-positive tumors and 85.4% for patients 
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with ERCC1-negative tumors (41 of 48 patients without progression of their 
disease). 
 
Discussion 
 
In the present study, we analyzed the immunohistochemical 
expression of ERCC1 in a series of patients with primary breast cancer. We 
showed an association between ERCC1-positive expression and tumor size 
smaller than 2.0 cm (P = 0.007), but no correlation was found with other 
clinicopathologic features. Although not statistically significant, the majority 
(72.7%) of special histological types of invasive breast carcinomas was 
positive for ERCC1 compared to invasive ductal carcinomas, which were 
ERCC1-positive in 51.1% of the cases. Tumors with ERCC1 expression were 
also associated with positivity for ER (P = 0.040), but there was no 
correlation between the expression of ERCC1 and the other biomarkers 
studied. We did not find a statistically significant association between 
ERCC1 expression and the molecular subtypes of breast cancer, but TNBC 
were more frequently negative for ERCC1 (61.5% of the cases) compared to 
the non-TNBC, which were negative for this protein in 41.5% of the cases.  
The expression of ERCC1 in breast cancer was analyzed in few 
studies. In a series of 504 women with early stage breast cancer treated with 
breast conserving surgery and breast irradiation, Goyal et al. (2010) [26] 
showed that an increased expression of ERCC1 was associated with features 
related to a better prognosis, including age > 50 years-old, lower T stage, 
nodal negativity, ER-positivity, and non-triple negative status. We found 
similar results regarding ERCC1-positive expression with smaller tumor size 
and ER-positivity. Our study and others showed that ERCC1 expression is 
lower in TNBC when compared to non-TNBC. Sidoni et al. (2008) [24] 
analyzed ERCC1 expression in 81 TNBC and found that around one third 
(32.0%) was positive for this protein. Another study with 230 breast cancer 
patients revealed a statistically significant correlation between ERCC1 
expression and the molecular subtypes of breast cancer (P = 0.013): ERCC1 
positivity was higher in luminal A subtype (69.7%) and lower in TNBC 
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(48.3%) and luminal B (43.5%) subtypes [25].  In general, invasive breast 
carcinomas classified as TNBC are high-grade ductal carcinomas, with 
nuclear pleomorphism and high mitotic index [5]. Interestingly, Handra-Luca 
et al. (2007) [23] showed that head and neck squamous cell carcinomas with 
lower levels of ERCC1 were histologically less differentiated than tumors 
with higher levels of this protein. 
Chemotherapy composed by platinum drugs result in the formation 
of platinum-DNA adducts leading to a distortion in the structure of the DNA 
molecule. These DNA adducts are repaired by enzymes related to the NER 
pathway, including ERCC1 [9-11]. The integrity of DNA repair systems, 
specially the NER pathway, is an important predictor of resistance to 
chemotherapy based on platinum drugs [12]. Wang et al. (2008) [15] studied 
46 malignant pleural or peritoneal effusions collected from patients with 
gastric cancer, gynecological cancer, and NSCLC and evaluated whether the 
mRNA levels of ERCC1 and breast cancer susceptibility gene 1 (BRCA1) of 
the collected samples were associated with in vitro chemosensitivity to 
cisplatin and/or docetaxel. The authors showed that for patients with NSCLC, 
higher mRNA levels of ERCC1 and BRCA1 in the pleural effusions were 
negatively correlated to chemosensitivity to cisplatin [15]. 
Currently, a variety of cancers are treated with platinum-based 
chemotherapy and the enzyme ERCC1 has been postulated as a possible 
useful predictive and/or prognostic biomarker to this kind of therapy. 
According to Olaussen et al. (2006) [19], the status of ERCC1 is a 
determinant factor for the sensitivity of NSCLC to platinum-based 
chemotherapy. The authors analyzed two groups of patients with completely 
resected NSCLC: the adjuvant chemotherapy group received cisplatin-based 
chemotherapy and the control group was only observed. Patients with 
ERCC1-negative tumors in the adjuvant chemotherapy group had a 
statistically significant better OS and DFS when compared to the control 
group; in contrast, there was no significant difference in survival between the 
two groups in patients with ERCC1-positive tumors [19]. In another study, 
the negativity for ERCC1 in patients with locally advanced NSCLC treated 
with platinum-based neoadjuvant concurrent chemoradiotherapy was 
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associated with a better survival compared to patients whose tumors were 
ERCC1-positive [20]. Similar results were found for patients treated with 
platinum regimens for advanced cancers, including gastric [16], colorectal 
[17, 18], urinary tract [21, 22], and head and neck cancers [23].  
Our study and those of Goyal et al. (2010) [26] and Kim et al. 
(2011) [25] did not find an association between ERCC1 expression and 
survival for patients with breast cancer. Other studies analyzed the expression 
of ERCC1 in patients with advanced breast cancer treated with platinum-
based regimens.  Shao et al. (2009) [27] studied 54 patients with locally 
advanced or metastatic breast cancer treated with paclitaxel and cisplatin and 
found that, in multivariate analysis, ERCC1-positivity was associated with a 
shorter progression free survival (PFS). A more recent study involving 107 
breast cancer patients treated with neoadjuvant chemotherapy composed of 
paclitaxel plus carboplatin showed that ERCC1-negative tumors were related 
with a higher pathological complete remission (pCR) than tumors positive for 
ERCC1. [28] In this study, the association of clinicopathologic variables with 
negativity for ERCC1, beta-tubulin III, and Bcl-2 was a stronger predictive 
factor for pCR compared to clinicopathologic variables alone or associated 
with molecular classification of breast cancer [28]. 
In general, our results and those from Goyal et al. (2010) [26] and 
Kim et al. (2011) [25] suggest that ERCC1 expression is associated with 
more favorable clinicopathologic features in patients with breast cancer, 
including an association with ER expression and luminal subtype. Some 
studies have shown that breast cancer patients whose tumors are ER-positive 
have a significantly lower pCR following neoadjuvant chemotherapy when 
compared to patients with tumors negative for ER [33, 34]. In the study of 
Chen et al. (2011) [28], patients with ER and PR negative tumors had a 
significantly higher pCR rate than those with tumors positive for hormonal 
receptors; and, among the molecular subtypes of breast cancer, luminal A 
tumors had the lowest pCR rate. Based on this, the 12th St Gallen 
International Expert Consensus on the Primary Therapy of Early Breast 
Cancer 2011 advocates that chemotherapy is less useful in patients with 
breast tumors classified as luminal A subtype, because this subtype is less 
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responsive to chemotherapy [4]. Our results and those from other studies 
suggest that the luminal subtype “resistance” to chemotherapy may be 
related, at least in part, to the integrity of the DNA repair pathways in this 
subtype, including the NER pathway [25, 26, 28]. 
In conclusion, the immunohistochemical expression of ERCC1 in 
our series of breast carcinomas correlated significantly with some favorable 
prognostic factors such as smaller tumor size and ER-positivity. In contrast to 
invasive ductal carcinomas, the majority of special histological types of 
invasive breast carcinomas are positive for ERCC1. Finally, the expression of 
this protein is lower in TNBC compared to the non-TNBC. Further 
investigation of ERCC1 expression in a larger population of advanced breast 
cancer patients treated with chemotherapy platinum-based regimens is 
warranted to help elucidate its possible role as a predictive and/or prognostic 
marker, as far as treatment response and survival are concerned. 
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Table 1 Clinicopathological characteristics of the 109 patients for whom 
ERCC1 immunochemistry was available 
Feature No. % 
Age (years)   
   < 50 26 23.9 
   ≥ 50 83 76.1 
Histological type   
   IDC 94 86.2 
   ILC 3 2.8 
   IC – Mixed 1 0.9 
   IC – Special type 11 10.1 
Histological grade   
   I 16 14.7 
   II 52 47.7 
   III 41 37.6 
Tumor size   
   < 2.0 cm 41 39.4 
   ≥ 2.0 cm 63 60.6 
Lymph node status   
   Negative 56 53.8 
   Positive 48 46.2 
ER   
   Negative 34 31.5 
   Positive 74 68.5 
PR   
   Negative 58 53.7 
   Positive 50 46.3 
HER2 status   
   Negative 100 92.6 
   Positive 8 7.4 
EGFR   
   Negative 61 92.4 
   Positive 5 7.6 
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Table 1 (continued) 
CK5 
  
   Negative 77 71.3 
   Positive 31 28.7 
P-cadherin   
   Negative 74 67.9 
   Positive 35 32.1 
Vimentin   
   Negative 43 82.7 
   Positive 9 17.3 
Molecular subtype   
   Luminal 75 69.4 
   HER2-overexpressing  7 6.5 
   TNBC 26 24.1 
Ki-67   
   Low proliferative 37 56.1 
   High proliferative 29 43.9 
ERCC1   
   Negative 51 46.8 
   Positive 58 53.2 
TNM stage   
   I 30 28.8 
   II 40 38.5 
   III 10 9.6 
   IV 24 23.1 
NPI   
   Good prognosis 20 21.3 
   Moderate prognosis 53 56.4 
   Poor prognosis 21 22.3 
CK5 cytokeratin 5, EGFR epidermal growth factor receptor, ER estrogen 
receptor, ERCC1 excision repair cross-complementation 1 enzyme, HER2 
human epidermal growth factor receptor 2, IC invasive carcinoma, IDC 
invasive ductal carcinoma, ILC invasive lobular carcinoma, NPI Nottingham 
Prognostic index, PR progesterone receptor, TNBC triple negative breast 
cancer 
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Table 2 Clinicopathological characteristics of the patients according to 
ERCC1 status 
 ERCC1 
negative  
H score < 0.2 
(n = 51) 
ERCC1 
positive 
H score ≥ 0.2 
(n = 58) 
P value 
Age (years)    
   < 50 9 (34.6) 17 (65.4) 0.154 
   ≥ 50 42 (50.6) 41 (49.4)  
Histological type    
   IDC 46 (48.9) 48 (51.1) 0.360 
   ILC 1 (33.3) 2 (66.7)  
   IC – Mixed 1 (100.0) 0 (0.0)  
   IC – Special type 3 (27.3) 8 (72.7)  
Histological grade    
   I 5 (31.3) 11 (68.8) 0.400 
   II 26 (50.0) 26 (50.0)  
   III 20 (48.8) 21 (51.2)  
Tumor size    
   < 2.0 cm 13 (31.7) 28 (68.3) 0.007* 
   ≥ 2.0 cm 37 (58.7) 26 (41.3)  
Lymph node status    
   Negative 26 (46.4) 30 (53.6) 0.565 
   Positive 25 (52.1) 23 (47.9)  
TNM stage    
   I 10 (33.3) 20 (66.7) 0.290 
   II 22 (55.0) 18 (45.0)  
   III 5 (50.0) 5 (50.0)  
   IV 13 (54.2) 11 (23.1)  
NPI    
   Good prognosis 8 (40.0) 12 (60.0) 0.508 
   Moderate 
prognosis 
28 (52.8) 25 (47.2)  
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 Table 2 (continued) 
Poor prognosis 
 
12 (57.1) 
 
9 (42.9) 
 
ERCC1 excision repair cross-complementation 1 enzyme, IC invasive 
carcinoma, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, 
NPI Nottingham Prognostic índex 
* P value is statiscally significant 
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Table 3 Biomarkers expression according to ERCC1 status 
 ERCC1 
negative H 
score < 0.2 
(n = 51) 
ERCC1 
positive 
H score ≥ 0.2 
(n = 58) 
P value 
ER    
   Negative 21 (61.8) 13 (38.2) 0.040* 
   Positive 30 (40.5) 44 (59.5)  
PR    
   Negative 27 (46.6) 31 (53.4) 0.881 
   Positive 24 (48.0) 26 (52.0)  
HER2    
   Negative 47 (47.0) 53 (53.0) 0.722 
   Positive 3 (37.5) 5 (62.5)  
EGFR    
   Negative 39 (63.9) 22 (36.1) 0.651 
   Positive 4 (80.0) 1 (20.0)  
CK5    
   Negative 39 (50.6) 38 (49.4) 0.153 
   Positive 11 (35.5) 20 (64.5)  
P-cadherin    
   Negative 34 (45.9) 40 (54.1) 0.798 
   Positive 17 (48.6) 18 (51.4)  
Vimentin    
   Negative 24 (55.8) 19 (44.2) 0.283 
   Positive 7 (77.8) 2 (22.2)  
Molecular subtype    
   Luminal 31 (41.3) 44 (58.7) 0.226 
   HER2-
overexpressing  
3 (42.9) 4 (57.1)  
   TNBC 16 (61.5) 10 (38.5)  
Ki-67    
   Low proliferative 25 (67.6) 12 (32.4) 0.642 
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  Table 3 (continued) 
 High proliferative 
 
18 (62.1) 
 
11 (37.9) 
 
CK5 cytokeratin 5, EGFR epidermal growth factor receptor, ER estrogen 
receptor, ERCC1 excision repair cross-complementation 1 enzyme, HER2 
human epidermal growth factor receptor 2, PR progesterone receptor, TNBC 
triple negative breast cancer 
* P value is statiscally significant 
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Figure Captions 
 
Fig. 1 Representative immunohistochemical staining for ERCC1 in breast 
cancer. a Diffuse expression for ERCC1 in the nuclei of breast tumor cells 
with intensity staining scored as 3 (H score = 3) (original magnification, 
x200). b Breast tumor tissue negative for ERCC1 expression (H score = 0) 
(original magnification, x200) 
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